Axogen Inc vs Docusign Inc — how do they compare? Axogen Inc trades at $48.35 (market cap $2.59B), while Docusign Inc trades at $59.22 (market cap $11.39B). The key difference: Docusign Inc is far larger — about 4.4× Axogen Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals.
| AXGN | DOCU | |
|---|---|---|
Market Cap | $2.59B | $11.39B |
Sector | Technology | Technology |
52-Week High | $48.48 | $85.01 |
52-Week Low | $14.16 | $41.75 |
Enterprise Value | $2.50B | $10.76B |
Signals from Pluang's Aura AI — not financial advice
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
DOCU trades at $60.26, up 5.91% today, reflecting strong momentum after consecutive earnings beats. The stock shows bullish technical signals with support at $58 and resistance at $61. Revenue grew to $2.98B in 2025, with net income surging to $1.07B, though cash flow turned negative. Analyst consensus is mixed with a $55.40 price target below the current price, indicating caution despite recent strength.
Outlook balances robust profitability and growth against high valuation and cash flow concerns. The stock offers upside if earnings momentum continues but faces risks from competitive pressures and reliance on subscription renewals. Institutional activity shows mixed signals with some funds reducing stakes.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →